iCAD

iCAD, Inc. is a medical technology company, which engages in the provision of cancer detection and therapy solutions. It operates through the Cancer Detection and Cancer Therapy segments. The Cancer Detection segment includes image analysis and workflow products. The Cancer Therapy segment is composed of radiation therapy products. The company was founded in 1984 and is headquartered in Nashua, NH.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

iCAD implements strategic changes to drive profitability and growth

iCAD is strategically focusing on cost reduction, revenue diversification, and transitioning to a subscription model to drive profitability by 2024. Leveraging partnerships with Google and other organizations, the company aims to expand its market reach and enhance operational efficiency. Despite facing competition and market challenges, iCAD remains optimistic about its growth prospects.

iCAD reports Q1 revenue decline, eyes growth in AI healthcare

iCAD faced revenue decline in Q1 2023, with a focus on detection and therapy segments, while maintaining a strong gross profit margin.
The company's Xoft technology and partnership with Google Health present promising growth opportunities in the AI healthcare space.
Challenges include lower-than-expected Xoft business revenue, competition in AI software, and delays in partnership agreements.

iCAD reports Q2 revenue decline, eyes growth through strategic partnerships

iCAD's Q2 2023 Earnings Call showcased a revenue decline but highlighted progress in the detection segment and strategic partnerships. The company aims for recurring revenue through subscription deals and is focused on cost reductions and stability. Opportunities lie in expanding partnerships and securing growth with healthcare facilities globally.

iCAD reports improved operational metrics and strategic partnerships in Q3 '23

iCAD's Q3 '23 earnings call highlighted operational improvements, strategic partnerships, and a focus on growth initiatives. Despite a revenue decline and operating loss, the company has made progress in reducing EBITDA loss and cash burn. iCAD's financial position remains stable with sufficient resources for planned operations.

iCAD reports improved financials and strategic growth initiatives for 2024

iCAD's financial performance showed improvements in revenue, EBITDA loss, and operational efficiency, driven by strategic initiatives.
The company's focus on AI solutions, geographic expansion, and recurring revenue model positions it for future growth.
While facing challenges in market adoption and OpEx increases, iCAD has opportunities to capitalize on market growth and new product developments.

iCAD reports revenue growth and strategic expansion in Q1 2024

iCAD's Q1 2024 performance reflects positive momentum with revenue growth, improved profitability metrics, and strategic advancements
The company's focus on innovation, market expansion, and cost control positions them well for future growth and market leadership
While challenges like revenue seasonality and competitive pressures exist, iCAD's strengths in product development and global expansion offer opportunities for sustained growth
Overall, iCAD's Q1 2024 earnings call underscores a promising outlook with a strong foundation for continued success in the medical technology sector

iCAD reports 4% revenue growth, FDA clearance boosts cancer detection

iCAD's Q3 performance reflects growth in revenue and strategic partnerships, underpinned by AI technology.
While facing challenges in service revenue and net loss, the company's global expansion and product advancements signal resilience.
Opportunities lie in market expansion, innovation in breast cancer detection, and transitioning to a recurring revenue model.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

iCAD, Inc. is a global medical technology company, which engages in the provision of cancer detection and therapy solutions. It operates through the Cancer Detection and Cancer Therapy segments. The Cancer Detection segment includes image analysis and workflow products. The Cancer Therapy segment relates to radiation therapy products. The company was founded in 1984 and is headquartered in Nashua, NH.

The ongoing market-wide sell-off has been ruthless against small-cap tickers, but the comprehensive selling has uncovered iCAD. The ticker is currently undervalued with an attractive risk-reward. ICAD has lost about 81% of its value over the past twelve months. I suspect we could see a "snapback" move in the near term.

iCAD: Another Great Candidate For My 'Bio Boom' Speculative Portfolio

NASHUA, N.H., Oct. 27, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the third quarter ended September 30, 2022, after the market close, and host a conference call at 4:30 PM Eastern Time on November 10, 2022.

iCAD to Report Third Quarter 2022 Financial Results on November 10, 2022

Array Technologies

DoubleVerify Holdings

Embark Technology

Gevo

Shockwave Medical

YETI

Although, on the surface, everything looks gloomy now for stocks, one point that the bears are forgetting, I would argue, is that we live in an era of unprecedented technological advancement. Never before in the world has there simultaneously been so many new, highly impactful technologies –from artificial intelligence to connected cars to fintech to autonomous vehicles to automated retail checkout devices.

7 Little-Known Stocks With Millionaire-Maker Potential

Flexible subscription model accelerates deployment of iCAD's Breast AI Suite, the only complete solution designed to comprehensively address today's top imaging challenges Flexible subscription model accelerates deployment of iCAD's Breast AI Suite, the only complete solution designed to comprehensively address today's top imaging challenges

iCAD Customers in the U.S. and Europe Increasingly Adopting Company's Full Suite of Breast AI Technologies via Subscription Model

Icad (ICAD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

After Plunging 29.6% in 4 Weeks, Here's Why the Trend Might Reverse for Icad (ICAD)

iCAD, Inc. (NASDAQ:ICAD ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Tony Takazawa - Director, Investor Relations Stacey Stevens - President and Chief Executive Officer Steve Sarno - Interim Chief Financial Officer Conference Call Participants Per Ostlund - Craig Hallum Capital Group Sam Eiber - BTIG Charlie Montang - Lake Street Capital Francois Brisebois - Oppenheimer Yale Jen - Laidlaw and Company Operator Good afternoon, ladies and gentlemen. And welcome to the iCAD, Inc. Second Quarter 2022 Earnings Call.

iCAD, Inc. (ICAD) CEO Stacey Stevens on Q2 2022 Results - Earnings Call Transcript

Icad (ICAD) delivered earnings and revenue surprises of 0% and 15.08%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Icad (ICAD) Reports Q2 Loss, Lags Revenue Estimates

Company reports accelerating demand for subscription and cloud-based business models driving long-term recurring revenue opportunities

iCAD Reports Financial Results For Second Quarter 2022

NASHUA, N.H., July 27, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the second quarter ended June 30, 2022, after the market close, and host a conference call at 4:30 PM Eastern Time on August 10, 2022.

iCAD to Report Second Quarter 2022 Financial Results on August 10, 2022

Compelling clinical evidence shows ProFound AI Risk accurately identified a high-risk group of women with 32 times higher risk of breast cancer than the general population Compelling clinical evidence shows ProFound AI Risk accurately identified a high-risk group of women with 32 times higher risk of breast cancer than the general population

iCAD Presents its Complete Suite of Breast Cancer AI Solutions at the European Congress of Radiology

Leading radiologists to highlight clinical examples demonstrating power of iCAD's complete suite of ProFound AI Breast Health Solutions Leading radiologists to highlight clinical examples demonstrating power of iCAD's complete suite of ProFound AI Breast Health Solutions

ProFound AI Risk Real-World Case Studies to be featured in iCAD's “ProFound Insights, ProFound Impact” Webinar Series

NASHUA, N.H., June 06, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will participate in the JMP Securities Life Sciences Conference, taking place June 15-16, 2022 in New York City.

iCAD to Present at the JMP Securities Life Sciences Conference on June 15-16, 2022

Frontline

Nordic American Tankers

Patterson-UTI Energy

Seagen

EPS estimates are generally a strong indication of future growth. That's just one part of finding reliable growth stocks.

5 Growth Stocks to Buy Now

Stephen P. Sarno appointed as interim Chief Financial Officer to the Company, effective immediately Stephen P. Sarno appointed as interim Chief Financial Officer to the Company, effective immediately

iCAD Announces CFO Transition

Using U.S. guidelines, ProFound AI Risk found 14% of women studied who had a negative screen had almost 20 times higher risk of developing breast cancer in the next year than the general risk population Using U.S. guidelines, ProFound AI Risk found 14% of women studied who had a negative screen had almost 20 times higher risk of developing breast cancer in the next year than the general risk population

New Research Finds iCAD's ProFound AI Risk for Digital Breast Tomosynthesis is 2.4x More Accurate than Traditional Lifetime Risk Models

NASHUA, NH / ACCESSWIRE / May 12, 2022 / iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will present at the Spring Into Action - Best Ideas Virtual Investor Conference, which is being held virtually on May 16th - 20th, 2022. Stacey Stevens, President and CEO of iCAD, Inc. will present on Tuesday, May 17, 2022, from 11:30 to 11:55 a.m.

iCAD to Present at the Spring Into Action - Best Ideas Virtual Investor Conference on May 17th, 2022

iCAD, Inc. (NASDAQ:ICAD ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Stacey Stevens – President & Chief Executive Officer Charles Carter – Chief Financial Officer Anthony Takazawa – Director, Investor Relations Conference Call Participants Per Ostlund – Craig-Hallum Marie Thibault – BTIG Yale Jen – Laidlaw & Company Frank Takkinen – Lake Street Capital Operator Good afternoon, ladies and gentlemen, and welcome to the iCAD, Inc. First Quarter 2022, Earnings Call. At this time, all participants have been placed on a listen-only mode, and we will open the floor for your questions and comments after the presentation.

iCAD, Inc. (ICAD) CEO Stacey Stevens on Q1 2022 Results - Earnings Call Transcript

Company to host conference call and webcast today at 4:30 PM ET Company to host conference call and webcast today at 4:30 PM ET

iCAD Reports Financial Results for First Quarter Ended March 31, 2022

NASHUA, N.H., April 27, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the first quarter ended March 31, 2022, after the market close, and host a conference call at 4:30 PM Eastern Time on Wednesday, May 11.

iCAD to Report First Quarter 2022 Financial Results on Wednesday, May 11

iCAD's award winning portfolio of breast health solutions to be featured at inaugural Pink Paradigm Summit, uniting clinical and advocacy leadership iCAD's award winning portfolio of breast health solutions to be featured at inaugural Pink Paradigm Summit, uniting clinical and advocacy leadership

iCAD Showcases Innovative Breast Health Solutions Platform at National Consortium of Breast Centers (NCoBC) 31st Annual Conference

NASHUA, N.H., March 09, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will participate in the virtual 32nd Annual Oppenheimer Healthcare Conference, taking place March 15-17, 2022.

iCAD to Present at the 32nd Annual Oppenheimer Healthcare Conference

iCAD, Inc. (ICAD) CEO Michael Klein on Q4 2021 Results - Earnings Call Transcript

Icad (ICAD) delivered earnings and revenue surprises of -54.55% and 0.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Icad (ICAD) Reports Q4 Loss, Lags Revenue Estimates

Launched ProFound AI® Risk, the world's first clinical decision support tool for short term breast cancer risk estimation

iCAD Reports Financial Results for Fourth Quarter and Year Ended December 31, 2021

Icad (ICAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for iCAD Stock (ICAD)